Skip to main content

Table 1 CYP26A1 expression and the clinical profiles of the cervical cancer tissue microarray

From: Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer

   CYP26A1 expression  
Variables Cases (n) Negative (%) Positive (%) P
Age (years)     
  <50 21 9 (42.9) 12 (57.1) 0.022*
  ≥50 29 22 (75.9) 7 (24.1)  
Primary tumor status (pT)     
  pTis 3 2 (66.7) 1 (33.3) 0.076
  pT1a 7 7 (100) 0 (0)  
  pT1b 35 18 (51.4) 17 (48.6)  
  pT2 5 4 (80.0) 1 (20.0)  
Lymph node involvement (pN)     
  Absent 31 24 (77.4) 7 (22.6) 0.016*
  Present 19 8 (42.1) 11 (57.9)  
pTNM stage     
  pStage 0 3 2 (66.7) 1 (33.3) 0.061
  pStage IA 7 7 (100) 0 (0)  
  pStage IB 20 13 (65.0) 7 (35.0)  
  pStage II 1 1 (100) 0 (0)  
  pStage III 19 8 (42.1) 11 (57.9)  
p53 expression     
  Absent 44 25 (56.8) 19 (43.2) 0.071
  Present 6 6 (100) 0 (0)  
Ki-67 labeling index     
  <20% 35 25 (71.4) 10 (28.6) 0.056
  ≥20% 15 6 (40.0) 9 (60.0)  
  1. *Significantly different by the chi-square (χ2) test.
  2. Abbreviations: CYP26A1, cytochrome P450, family 26, subfamily A, polypeptide 1; pTNM, pathological tumor-node-metastasis